Werewolf Therapeutics posts Q2 profit on Jazz asset sale
HOWL•Cash position and outlook
The company said it has repaid all debt to K2 HealthVentures and expects its cash to fund operations into the second quarter of 2027.
Werewolf also said it expects updates on strategic alternatives and clinical trial data in the second half of 2026, while noting that the timeline and outcome of the strategic alternatives process remain uncertain.
Research and development expenses fell to $6.2 million from $13.1 million a year ago.
Q2 profit driven by Jazz asset sale
Werewolf Therapeutics reported second-quarter collaboration revenue of $21 million from the sale of its JZP898 program to Jazz Pharmaceuticals, helping the biopharma company post net income of $3.67 million for the quarter, or $0.08 per basic share.
The result reversed a loss in the year-earlier period. Operating expenses totaled $13.84 million, while operating income was $7.16 million.
